Georgetown University Lombardi Cancer Center Support Grant

乔治敦隆巴迪综合癌症中心（LCCC）的使命是预防、治疗和 通过将科学发现、专家和富有同情心的患者护理、优质教育和 与社区建立伙伴关系，遵循cura personalis（"照顾整个人"）原则。 LCCC由董事Louis M.韦纳，医学博士，医学肿瘤学家和免疫治疗专家，与 副局长迈克尔B的支持。阿特金斯，医学博士，六个副主任（广告）和桑德拉M。斯温 LCCC的临床网络代表。四项研究计划-乳癌、癌症预防及 控制，实验治疗和分子肿瘤学-进行高影响力的研究， 9共享资源LCCC有91个成员，目前每年的同行评审总额为2870万美元。 （1850万美元NCI）以癌症为重点的资金（直接费用），导致1，100名同行评审的癌症相关 2009 - 2012年的出版物;其中32%涉及计划内和/或计划间合作，53%涉及计划内和/或计划间合作。 其中包括外部合作。2012年，LCCC安排了244名患者进行干预性临床试验 (13%的新患者）。显著的成就包括：1）发现了一种变革性的方法， 上皮细胞重编程，快速转化为临床试验; 2）开发使能工具， 作为药物再利用和集成信息平台的新型计算模型; 3）基础发现 （基因组不稳定性的新机制;尤文肉瘤中的转录靶向;耐药性） EGFR网络中的决定因素）; 4）高影响力临床试验的领导（例如，评价 帕妥珠单抗在乳腺癌中的作用，苯达莫司汀在滤泡性淋巴瘤中的作用）; 5）国家合作 为筛查乳腺X线摄影指南提供信息的建模研究，以及6）操作增强， 包括创建MedStar乔治敦癌症网络，以扩大LCCC的临床研究 在最近招募的Giuseppe Giaccone，MD，PhD（AD，临床研究）的指导下，集水区; 重组临床试验管理和监管活动，以更好地支持网络;以及 继续发展社区外展和研究地点， 哥伦比亚。

The mission of the Georgetown Lombardi Comprehensive Cancer Center (LCCC) is to prevent, treat and cure cancers by linking scientific discovery, expert and compassionate patient care, quality education, and partnership with the community, guided by the principle of cura personalis ("care for the whole person"). LCCC is led by Director Louis M. Weiner, MD, a medical oncologist and immunotherapy expert, with the support of Deputy Director Michael B. Atkins, MD, six Associate Directors (ADs) and Sandra M. Swain, LCCC's clinical network representative. Four Research Programs—Breast Cancer, Cancer Prevention and Control, Experimental Therapeutics and Molecular Oncology—conduct high-impact studies supported by nine Shared Resources. LCCC has 91 members, with a current annual total of $28.7M in peer-reviewed ($18.5M NCI) cancer-focused funding (direct costs), resulting in 1,100 peer-reviewed cancer-related publications from 2009-2012; 32% of which involved intra- and/or interprogrammatic collaborations, and 53% of which involved external collaborations. In 2012, LCCC placed 244 patients on interventional clinical trials (13% of new patients). Notable accomplishments include: 1) discovery of a transformative methodology for epithelial cell reprogramming with rapid translation into clinical trials; 2) development of enabling tools such as novel computational modeling for drug repurposing and integrated informatic platforms; 3) basic discovery (novel mechanisms for genomic instability; transcriptional targeting in Ewing sarcoma; resistance determinants in the EGFR network); 4) leadership of high-impact clinical trials (e.g., evaluation of pertuzumab in breast cancer, role of bendamustine in follicular lymphoma); 5) national collaborative modeling research informing screening mammography guidelines and 6) operational enhancements that include creation of the MedStar Georgetown Cancer Network to expand clinical research in LCCC's catchment area under the direction of recent recruit, Giuseppe Giaccone, MD, PhD (AD, Clinical Research); a reorganization of clinical trial management and regulatory activities to better support the Network; and the continued development of community outreach and research sites in the poorest wards of the District of Columbia.